Is GSK Quietly Becoming An Oncology Powerhouse
Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems Bewildering
Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout
GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
US FDA approves GSK's oral antibiotic for drug-resistant UTIs
FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention
GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder
Is GSK PLC (GSK) Overvalued After 3.3% Rally? GF Value Says Overvalued
Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal
GSK plc (GSK) M&A Call Transcript
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL
GSK's Nuvalent deal tackles HIV cliff to win cautious backing from analysts
Thistle Resources intersects broad gold mineralization at Middle River
Snail Games brings Bellwright to PlayStation and Xbox as console push advances
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share
Abacus Global Management launches AI lifespan modeling platform
After shedding its cancer business just over a decade ago, GSK's new CEO is building back with a $10.6 billion deal
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout
GSK Acquires Nuvalent for $10.6 Billion to Enhance Cancer Pipeline
Tuesday's Morning Movers: MU Rebounds, ON PT Increases & GSK Buys NUVL
5 Things to Know Before the Stock Market Opens
Nuvalent Catapults To Record High On GSK's $10.6 Billion All-Cash Bid
Nuvalent Stock Soars on $10.6 Billion GSK Buyout
GSK Agrees $10.6 Billion Nuvalent Deal at 40% Premium
Breakfast News: CRM & ACN Lead Wave Of M&A Action
GSK's $10.6B Nuvalent takeover fails to impress investors as shares fall: here's why
Cancer-Drug Stock Jumps 39% on $10.6 Billion GSK Deal. Why It's a Surprise Move.
GSK falls as £8bn takeover of Nuvalent is largest deal in a decade
London's FTSE 100 falls as GSK slides after Nuvalent deal
GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down
GSK agrees $10.6bn Nuvalent takeover to bolster oncology pipeline
GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
UK's GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
GSK in talks to buy cancer biotech Nuvalent for more than $9 billion, FT reports
Engitix Announces Strategic Collaboration with GSK to Advance First-in-Class Targets for Liver Fibrosis Regression
Longspur initiates on Gelion with 153p target, saying its battery tech can undercut China
FTSE 100 drops amid China banking concerns and falling oil prices
US bank sees GSK oncology pipeline as major value driver after New York conference
US bank sees GSK oncology pipeline as major value driver after New York conference
Gunnison Copper targets resource expansion with new district-wide drill program at flagship Arizona project
GSK plc (GSK) Presents at Jefferies Global Healthcare Conference 2026 Transcript
GSK Bets on Specialty Medicines to Drive Long-Term Revenue Growth
UBS says UK stocks are better supported but not broadly so, as earnings lead while sentiment drags
Why Is Glaxo (GSK) Down 2.1% Since Last Earnings Report?